Trinity College Dublin (TCD) hosted its first meeting and meeting of consortium partners on the PARADISE project taking place from 3rd to 4th April in Dublin. The PARADISE project (PersonAlisation of RelApse risk in autoimmune DISEase) aims to develop a personalized tool for predicting the risk of relapse of the disease in a patient, so that drug dosages can be adjusted, reduced and even stopped, and gathers a wide range of partners from Europe as part of the call ERA PerMed Joint translational call for proposals (2022) for “Prevention in personalized Medicine”.

The project is coordinated by prof. Ph.D.  Mark Little from the Trinity Translational Medicine Institute and the ADAPT Center at Trinity College Dublin, and one of the partners is the Catholic University of Croatia. Asst. Ph.D. Anto Čartolovni, Head of the Laboratory for Ethics of Digital Technologies in Healthcare and assistant professor at the Faculty of Medicine of the Catholic University of Croatia as part of PARADISE, is the head of one part of the work package WP5 – Transparent and Explainable prediction. At the meeting in Dublin, Assoc. Ph.D. Čartolovni presented the group’s work plan, goals and activities that will be realized in the next 36 months of the project.

You can find more information at the link.